Petros Pharmaceuticals Inc Stock

$0.26

4.18% yesterday

Nasdaq, Nov 15, 10:00 pm CET

ISIN

US71678J1007

Symbol

PTPI

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Petros Pharmaceuticals Inc Stock price

$0.26

-35.24 99.27% 5Y

Nasdaq, Closing price Fri, Nov 15 2024

-0.01 4.18%

ISIN

US71678J1007

Symbol

PTPI

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$2.59m
Enterprise Value	$3.88m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	0.56
P/S ratio (TTM) P/S ratio	0.37
P/B ratio (TTM) P/B ratio	0.83
Revenue (TTM) Revenue	$6.98m
EBIT (operating result TTM) EBIT	$-9.82m
Free Cash Flow (TTM) Free Cash Flow	$-6.94m
Cash position	$3.89m
EPS (TTM) EPS	$-6.21
P/E forward	negative
P/S forward	0.50
EV/Sales forward	0.74
Short interest	2.19%

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Get Started for Free Today

Petros Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

??

1 Analyst has issued a forecast Petros Pharmaceuticals Inc:

1x Buy

100%

More details on Analyst Estimates Including Price Targets

1 Analyst has issued a forecast Petros Pharmaceuticals Inc:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Petros Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '23		+/- %
Revenue	6.98 6.98	- 100%
- Direct Costs	5.75 5.75	- 82%
Gross Profit	1.23 1.23	- 18%
- Selling and Administrative Expenses	5.81 5.81	- 83%
- Research and Development Expense	1.75 1.75	- 25%
EBITDA	-6.33 -6.33	- -91%
- Depreciation and Amortization	3.49 3.49	- 50%
EBIT (Operating Income) EBIT	-9.82 -9.82	- -141%
Net Profit	-13 -13	- -182%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Petros Pharmaceuticals Inc Stock News

Neutral

Accesswire

●

2 months ago

Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

Company is currently conducting larger scale comprehension test to confirm results in compliance with FDA discussions NEW YORK, NY / ACCESSWIRE / September 11, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, today announced results of an initial...

Neutral

Accesswire

●

2 months ago

Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

NEW YORK, NY / ACCESSWIRE / September 3, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter ("OTC") drug development programs, announces today that Fady Boctor, President and Chief Commercial Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference.

Neutral

Accesswire

●

4 months ago

Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

Utilization of the Company's proprietary Web App showed improved self-selection utilizing an embedded validated diagnostic questionnaire compared to a live interview furthering the Company's efforts to potentially create a first-ever Rx-to-OTC switch in the ED category NEW YORK, NY / ACCESSWIRE / July 29, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company f...

More Petros Pharmaceuticals Inc News

Company Profile

Petros Pharmaceuticals, Inc. is a pharmaceutical company focused on men's health therapeutics. Its commercial capabilities include sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. The firm operates through Prescription Medications and Medical Devices segments. The Prescription Medications segment consists primarily of Stendra, which is sold generally in the United States. The Medical Devices segment includes vacuum erection devices, which are sold domestically and internationally. The company was founded on May 14, 2020 and is headquartered in New York, NY.

Head office	United States
CEO	John Shulman
Employees	21
Website	www.petrospharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now